Clinical outcome according to timing of cabergoline initiation for prevention of OHSS: A randomized controlled trial

Reproductive BioMedicine Online

Volumn 26, Issue 6, 2013, Pages 562-568

  Seow, Kok Min ^a,b   Lin, Yu Hung ^a,c,e   Bai, Chyi Huey ^d   Chen, Heng Ju ^a,c   Hsieh, Bih Chwen ^a,c   Huang, Lee Wen ^a,c   Tzeng, Chii Ruey ^e   Hwang, Jiann Loong ^a,e  

^a SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

cabergoline; fertilization rate; metaphase II rate; oocyte maturation; ovarian hyperstimulation syndrome; pregnancy rate

Indexed keywords

BUSERELIN ACETATE; CABERGOLINE; PROGESTERONE; RECOMBINANT CHORIONIC GONADOTROPIN; RECOMBINANT FOLLITROPIN;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; FEMALE INFERTILITY; FERTILIZATION; FERTILIZATION IN VITRO; HUMAN; INCIDENCE; INTRACYTOPLASMIC SPERM INJECTION; MAJOR CLINICAL STUDY; METAPHASE; OOCYTE MATURATION; OOCYTE RETRIEVAL; OVARY HYPERSTIMULATION; PREGNANCY RATE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; DOPAMINE AGONISTS; ERGOLINES; FEMALE; HUMANS; OVARIAN HYPERSTIMULATION SYNDROME; PREGNANCY; TREATMENT OUTCOME;

EID: 84878536642     PISSN: 14726483     EISSN: 14726491     Source Type: Journal    
DOI: 10.1016/j.rbmo.2013.03.002     Document Type: Article

References (30)

1. M.A. Aboulghar, and R.T. Mansour Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures Hum. Reprod. Update 9 2003 275 289 (Pubitemid 36827064)
2. C. Alvarez, L. Marti-Bonmati, E. Novella-Maestre, R. Sanz, R. Gomez, M. Fernandez-Sanchez, C. Simón, and A. Pellicer Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction J. Clin. Endocrinol. Metab. 92 2007 2931 2937 (Pubitemid 47236352)
3. D.O. Bates, and S.J. Harper Regulation of vascular permeability by vascular endothelial growth factors Vascul. Pharmacol. 39 2002 225 237 (Pubitemid 37490748)
4. X. Cao, P. Zhou, H. Luo, Y. Zhao, and G. Shi The effect of VEGF on the temporal-spatial change of alpha-tubulin and cortical granules of ovine oocytes matured in vitro Anim. Reprod. Sci. 113 2009 236 250
5. C. Carizza, V. Abdelmassih, S. Abdelmassih, P. Ravizzini, L. Salgueiro, P.T. Salgueiro, L.T. Jine, P. Nagy, and R. Abdelmassih Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study Reprod. Biomed. Online. 17 2008 751 755
6. A. Delvigne, and S. Rozenberg Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review Hum. Reprod. Update 8 2002 559 577 (Pubitemid 35452781)
7. I.M. Ebisch, C.M. Thomas, A.M. Wetzels, W.N. Willemsen, F.C. Sweep, and R.P. Steegers-Theunissen Review of the role of the plasminogen activator system and vascular endothelial growth factor in subfertility Fertil. Steril. 90 2008 2340 2350
8. H. Gille, J. Kowalski, B. Li, J. LeCouter, B. Moffat, T.F. Zioncheck, N. Pelletier, and N. Ferrara Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants J. Biol. Chem. 276 2001 3222 3230
9. A. Golan, R. Ron-el, A. Herman, Y. Soffer, Z. Weinraub, and E. Caspi Ovarian hyperstimulation syndrome: an update review Obstet. Gynecol. Surv. 44 1989 430 440 (Pubitemid 19138981)
10. R. Gomez, C. Simon, J. Remohi, and A. Pellicer Administration of moderate and high doses of gonadotropins to female rats increases ovarian vascular endothelial growth factor (VEGF) and VEGF receptor-2 expression that is associated to vascular hyperpermeability Biol. Reprod. 68 2003 2164 2171 (Pubitemid 36687009)
11. R. Gomez, M. Gonzalez-Izquierdo, R.C. Zimmermann, E. Novella-Maestre, I. Alonso-Muriel, J. Sanchez-Criado, J. Remohi, C. Simon, and A. Pellicer Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model Endocrinology 147 2006 5400 5411 (Pubitemid 44790595)
12. J.L. Hwang, K.M. Seow, Y.H. Lin, B.C. Hsieh, L.W. Huang, H.J. Chen, S.C. Huang, C.Y. Chen, P.H. Chen, and C.R. Tzeng IVF versus ICSI in sibling oocytes from patients with polycystic ovarian syndrome: a randomized controlled trial Hum. Reprod. 20 2005 1261 1265
13. B. Jones, P. Jarvis, J.A. Lewis, and A.F. Ebbutt Trials to assess equivalence: the importance of rigorous methods BMJ 313 1996 36 39 (Pubitemid 26229889)
14. M.M. Kaczmarek, D. Schams, and A.J. Ziecik Role of vascular endothelial growth factor in ovarian physiology - an overview Reprod. Biol. 5 2005 111 136
15. U.B. Kaiser The pathogenesis of the ovarian hyperstimulation syndrome N. Engl. J. Med. 349 2003 729 732 (Pubitemid 37010776)
16. O. Levinsohn-Tavor, S. Friedler, M. Schachter, A. Raziel, D. Strassburger, and R. Ron-El Coasting - what is the best formula? Hum. Reprod. 18 2003 937 940 (Pubitemid 36592031)
17. J.A. Lewis Statistical principles for clinical trials (ICH E9): an introductory note on an international guideline Stat. Med. 18 1999 1903 1942
18. Y.H. Lin, K.M. Seow, B.C. Hsieh, L.W. Huang, H.J. Chen, S.C. Huang, C.Y. Chen, P.H. Chen, J.L. Hwang, and C.R. Tzeng Application of GnRH antagonist in combination with clomiphene citrate and hMG for patients with exaggerated ovarian response in previous IVF/ICSI cycles J. Assist. Reprod. Genet. 24 2007 331 336
19. H. Luo, K. Kimura, M. Aoki, and M. Hirako Effect of vascular endothelial growth factor on maturation, fertilization and developmental competence of bovine oocytes J. Vet. Med. Sci. 64 2002 803 806
20. M. Manno Can we eliminate severe ovarian hyperstimulation syndrome? Comment I Hum. Reprod. 20 2005 2368 2369 author reply 2369-2370
21. M. Manno, F. Tomei, E. Marchesan, and V. Adamo Cabergoline: a safe, easy, cheap, and effective drug for prevention/treatment of ovarian hyperstimulation syndrome? Eur. J. Obstet. Gynecol. Reprod. Biol. 122 2005 127 128 (Pubitemid 41265694)
22. R.S. Mathur, A.V. Akande, S.D. Keay, L.P. Hunt, and J.M. Jenkins Distinction between early and late ovarian hyperstimulation syndrome Fertil. Steril. 73 2000 901 907 (Pubitemid 30227512)
23. N. McClure, D.L. Healy, P.A. Rogers, J. Sullivan, L. Beaton, R.V. Haning Jr, D.T. Connolly, and D.M. Robertson Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome Lancet 344 1994 235 236 (Pubitemid 24229013)
24. E.G. Papanikolaou, C. Pozzobon, E.M. Kolibianakis, M. Camus, H. Tournaye, H.M. Fatemi, A. Van Steirteghem, and P. Devroey Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles Fertil. Steril. 85 2006 112 120 (Pubitemid 43063432)
25. S.R. Soares Etiology of OHSS and use of dopamine agonists Fertil. Steril. 97 2012 517 522
26. S.R. Soares, R. Gomez, C. Simon, J.A. Garcia-Velasco, and A. Pellicer Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome Hum. Reprod. Update 14 2008 321 333 (Pubitemid 351858972)
27. H. Tang, T. Hunter, Y. Hu, S.D. Zhai, X. Sheng, and R.J. Hart Cabergoline for preventing ovarian hyperstimulation syndrome Cochrane Database Syst. Rev. 2 2012 CD008605
28. A.C. Van Steirteghem, Z. Nagy, H. Joris, J. Liu, C. Staessen, J. Smitz, A. Wisanto, and P. Devroey High fertilization and implantation rates after intracytoplasmic sperm injection Hum. Reprod. 8 1993 1061 1066 (Pubitemid 23204690)
29. T.H. Wang, S.G. Horng, C.L. Chang, H.M. Wu, Y.J. Tsai, H.S. Wang, and Y.K. Soong Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor J. Clin. Endocrinol. Metab. 87 2002 3300 3308
30. R.C. Zimmermann, T. Hartman, S. Kavic, S.A. Pauli, P. Bohlen, M.V. Sauer, and J. Kitajewski Vascular endothelial growth factor receptor 2-mediated angiogenesis is essential for gonadotropin-dependent follicle development J. Clin. Invest. 112 2003 659 669 (Pubitemid 38057707)